Compare SIGA & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIGA | TNXP |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 199.7M |
| IPO Year | 2016 | 2008 |
| Metric | SIGA | TNXP |
|---|---|---|
| Price | $3.15 | $5.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 590.9K | ★ 889.4K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 18.93% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $319.65 |
| Revenue Next Year | $170.70 | $101.60 |
| P/E Ratio | $24.38 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $2.83 | $6.01 |
| 52 Week High | $8.54 | $20.58 |
| Indicator | SIGA | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 14.28 |
| Support Level | $2.87 | N/A |
| Resistance Level | $3.32 | $12.99 |
| Average True Range (ATR) | 0.14 | 0.55 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 17.97 | 0.59 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.